This application relates to a composition for preventing, treating, and improving skeletal muscle atrophy, the composition including an organoselenium compound. The composition recovered the thickness of muscle fiber reduced by dexamethasone treatment. In addition, the treatment of mice in a muscle loss model showed that the composition had an effect of reducing damaged muscle and of restoring muscle mass. Therefore, it is expected that the composition can be effectively used for the treatment, prevention, or improvement of muscle atrophy.

This application relates to a composition for preventing, treating, and improving skeletal muscle atrophy, the composition including an organoselenium compound. The composition recovered the thickness of muscle fiber reduced by dexamethasone treatment. In addition, the treatment of mice in a muscle loss model showed that the composition had an effect of reducing damaged muscle and of restoring muscle mass. Therefore, it is expected that the composition can be effectively used for the treatment, prevention, or improvement of muscle atrophy.

The invention relates to 20-hydroxyecdysone and the derivatives thereof, for use in the treatment of genetic myopathies.

The invention relates to 20-hydroxyecdysone and the derivatives thereof, for use in the treatment of genetic myopathies.

The present invention relates to a composition for preventing, improving or treating muscle atrophy, which includes Gryllus bimaculatus, and more particularly, a Gryllus bimaculatus powder or Gryllus bimaculatus protein extract, as an active ingredient, and a method of preparing the same. The composition according to the present invention is effective in inhibiting the expression of muscle atrophy-associated key transcription factors, such as FoxO3 and MuRF-1, and is expected to be effectively used in muscle atrophy, various diseases caused thereby, muscle aging, undernourished patients, growing children and the elderly.

The present invention relates to a composition for preventing, improving or treating muscle atrophy, which includes Gryllus bimaculatus, and more particularly, a Gryllus bimaculatus powder or Gryllus bimaculatus protein extract, as an active ingredient, and a method of preparing the same. The composition according to the present invention is effective in inhibiting the expression of muscle atrophy-associated key transcription factors, such as FoxO3 and MuRF-1, and is expected to be effectively used in muscle atrophy, various diseases caused thereby, muscle aging, undernourished patients, growing children and the elderly.

The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduced to a subject by systemic administration. Specifically, the invention relates to methods comprising the in vivo delivery of short interfering nucleic acid (siNA) molecules that target a myostatin gene expressed by a subject, wherein the siNA molecule is conjugated to a lipophilic moiety, such as cholesterol. The myostatin siNA conjugates that are delivered as per the methods disclosed are useful to modulate the in vivo expression of myostatin, increase muscle mass and/or enhance muscle performance. Use of the disclosed methods is further indicated for treating musculoskeletal diseases or disorders and/or diseases or disorders that result in conditions in which muscle is adversely affected.

In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42.

In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42.

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating Facioscapulohumeral muscular dystrophy.